102 related articles for article (PubMed ID: 28599617)
1. Insight into the key features for ligand binding in Y1230 mutated c-Met kinase domain by molecular dynamics simulations.
Yan L; Zhang L; Zhang Y; Qiao X; Pan J; Liu H; Lu S; Xiang B; Lu T; Yuan H
J Biomol Struct Dyn; 2018 Jun; 36(8):2015-2031. PubMed ID: 28599617
[TBL] [Abstract][Full Text] [Related]
2. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.
Timofeevski SL; McTigue MA; Ryan K; Cui J; Zou HY; Zhu JX; Chau F; Alton G; Karlicek S; Christensen JG; Murray BW
Biochemistry; 2009 Jun; 48(23):5339-49. PubMed ID: 19459657
[TBL] [Abstract][Full Text] [Related]
3. Identification of Phytochemicals Targeting c-Met Kinase Domain using Consensus Docking and Molecular Dynamics Simulation Studies.
Aliebrahimi S; Montasser Kouhsari S; Ostad SN; Arab SS; Karami L
Cell Biochem Biophys; 2018 Jun; 76(1-2):135-145. PubMed ID: 28852971
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
Cui JJ; McTigue M; Nambu M; Tran-Dubé M; Pairish M; Shen H; Jia L; Cheng H; Hoffman J; Le P; Jalaie M; Goetz GH; Ryan K; Grodsky N; Deng YL; Parker M; Timofeevski S; Murray BW; Yamazaki S; Aguirre S; Li Q; Zou H; Christensen J
J Med Chem; 2012 Sep; 55(18):8091-109. PubMed ID: 22924734
[TBL] [Abstract][Full Text] [Related]
5. Electrostatic explanation of D1228V/H/N-induced c-Met resistance and sensitivity to type I and type II kinase inhibitors in targeted gastric cancer therapy.
Xu Z; Hu P; Fang D; Ni L; Xu J
J Mol Model; 2019 Jan; 25(1):13. PubMed ID: 30607513
[TBL] [Abstract][Full Text] [Related]
6. Studying the Binding Modes of Novel 2-Aminopyridine Derivatives as Effective and Selective c-Met Kinase Type 1 Inhibitors Using Molecular Modeling Approaches.
Ye Q; Fu C; Li J
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374386
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR-aided design of potent c-Met inhibitors using molecular dynamics simulation and binding free energy calculation.
Balasubramanian PK; Balupuri A; Bhujbal SP; Cho SJ
J Biomol Struct Dyn; 2019 May; 37(8):2165-2178. PubMed ID: 30044205
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and molecular modeling studies of new series of antitumor 1,2,4-triazines with potential c-Met kinase inhibitory activity.
El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
Bioorg Chem; 2018 Feb; 76():154-165. PubMed ID: 29175587
[TBL] [Abstract][Full Text] [Related]
9. Identification of triazolo[4,5-b]pyrazine derivatives as hepatocyte growth factor receptor inhibitors through structure-activity relationships and molecular docking simulations.
Dong M; Ren Y; Gao X
Bioorg Med Chem Lett; 2015 Oct; 25(19):4118-26. PubMed ID: 26321362
[TBL] [Abstract][Full Text] [Related]
10. A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients.
Tiedt R; Degenkolbe E; Furet P; Appleton BA; Wagner S; Schoepfer J; Buck E; Ruddy DA; Monahan JE; Jones MD; Blank J; Haasen D; Drueckes P; Wartmann M; McCarthy C; Sellers WR; Hofmann F
Cancer Res; 2011 Aug; 71(15):5255-64. PubMed ID: 21697284
[TBL] [Abstract][Full Text] [Related]
11. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
Zhao F; Zhang LD; Hao Y; Chen N; Bai R; Wang YJ; Zhang CC; Li GS; Hao LJ; Shi C; Zhang J; Mao Y; Fan Y; Xia GX; Yu JX; Liu YJ
Eur J Med Chem; 2017 Jul; 134():147-158. PubMed ID: 28411455
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors.
Liu M; Hou Y; Yin W; Zhou S; Qian P; Guo Z; Xu L; Zhao Y
Eur J Med Chem; 2016 Aug; 119():96-108. PubMed ID: 27155466
[TBL] [Abstract][Full Text] [Related]
13. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
14. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
[TBL] [Abstract][Full Text] [Related]
15. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations.
Tanizaki J; Okamoto I; Okamoto K; Takezawa K; Kuwata K; Yamaguchi H; Nakagawa K
J Thorac Oncol; 2011 Oct; 6(10):1624-31. PubMed ID: 21716144
[TBL] [Abstract][Full Text] [Related]
16. Large-Scale Virtual Screening Against the MET Kinase Domain Identifies a New Putative Inhibitor Type.
Bresso E; Furlan A; Noel P; Leroux V; Maina F; Dono R; Maigret B
Molecules; 2020 Feb; 25(4):. PubMed ID: 32093126
[TBL] [Abstract][Full Text] [Related]
17. Type II c-Met inhibitors: molecular insight into crucial interactions for effective inhibition.
Damghani T; Elyasi M; Pirhadi S; Haghighijoo Z; Ghazi S
Mol Divers; 2022 Jun; 26(3):1411-1423. PubMed ID: 34247323
[TBL] [Abstract][Full Text] [Related]
18. Structure-Based Drug Design Studies Toward the Discovery of Novel Chalcone Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors.
Al-Anazi M; Al-Najjar BO; Khairuddean M
Molecules; 2018 Dec; 23(12):. PubMed ID: 30563058
[TBL] [Abstract][Full Text] [Related]
19. Clustering and Sampling of the c-Met Conformational Space: A Computational Drug Discovery Study.
Mashayekh K; Sharifi S; Damghani T; Elyasi M; Avestan MS; Pirhadi S
Comb Chem High Throughput Screen; 2019; 22(9):635-648. PubMed ID: 31696808
[TBL] [Abstract][Full Text] [Related]
20. Discovery of [1,2,4]triazolo[3,4-b][1,3,4]thiadiazole derivatives as novel, potent and selective c-Met kinase inhibitors: Synthesis, SAR study, and biological activity.
Zhang L; Zhao J; Zhang B; Lu T; Chen Y
Eur J Med Chem; 2018 Apr; 150():809-816. PubMed ID: 29602036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
